Studying clot risk in lung cancer patients receiving immunotherapy
Studies blood clot risk in lung cancer patients receiving immune checkpoint inhibitor treatment.
Key facts
- Who runs it
- Beijing Chao Yang Hospital
- Where
- Beijing, Hohhot, and Zhengzhou, ChinaSee the 5 sites
- Trial code
- Registry title
- Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
- Status
- Recruiting
- People taking part
- 2,400 people, planned
- Started
- 1 Jan 2019
- Expected to end
- 1 Dec 2027
- Type of study
- Observational, 4 groups
- Record updated
- 30 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with confirmed lung cancer who have received at least one dose of an approved immune checkpoint inhibitor. It studies blood clots linked to this treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Lung cancer confirmed by tissue examination (histopathology)
- Earlier treatment
- Must have received at least one dose of a China-approved lung cancer immune checkpoint inhibitor
Main reasons for not taking part
- Two or more primary cancers
- Missing data for key variables
- Cannot comply with follow-up requirements
- Venous or arterial blood clot (VTE/ATE) when the immune checkpoint inhibitor was started
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age ≥18 years
- Histopathologically confirmed lung cancer diagnosis at enrollment
- Received at least one dose of a China-approved lung cancer immune checkpoint inhibitor
- Signed informed consent form
Who cannot take part
- Presence of two or more primary cancers
- Missing data for key variables
- Inability to comply with follow-up requirements
- Presence of VTE/ATE at the time of ICI initiation
Where in China
- Beijing Chaoyang Hospital, Capital Medical UniversityBeijing, ChinaContact: Yuhui ZhangTaking people
- Beijing Luhe Hospital, Capital Medical UniversityBeijing, ChinaContact: Yuan YuanTaking people
- China-Japan Friendship HospitalBeijing, ChinaContact: Meng YangTaking people
- The Fourth Hospital of Inner Mongolia Autonomous RegionHohhot, ChinaContact: Jing ZhaoTaking people
- The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaContact: Yanping SuTaking people
About the trial
What the trial wants to find out
The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint inhibitors (ICIs) therapy. The primary questions it aims to address are:
Read full original descriptionShow less
1. What is the real-world incidence of VTE/ATE in lung cancer patients receiving immune checkpoint inhibitors? 2. What are the risk factors and biomarkers for VTE/ATE in lung cancer patients receiving immune checkpoint inhibitors? 3. What is the impact of VTE/ATE on the prognosis of lung cancer patients receiving immune checkpoint inhibitors?
Researchers will compare the characteristics and biomarkers of patients with and without ICI-associated VTE/ATE to identify novel specific biomarkers for thrombotic events. Furthermore, they will construct a risk assessment model for thrombotic events to provide guidance for precision prevention and treatment in clinical practice.
The 4 groups in the trial
- With immune checkpoint inhibitor-associated venous thromboembolism
Patients with immune checkpoint inhibitor-associated venous thromboembolism would be included in this group
- Without immune checkpoint inhibitor-associated venous thromboembolism
Patients without immune checkpoint inhibitor-associated venous thromboembolism would be included in this group
- With immune checkpoint inhibitor-associated arterial thromboembolism
Patients with immune checkpoint inhibitor-associated arterial thromboembolism would be included in this group
- Without immune checkpoint inhibitor-associated arterial thromboembolism
Patients without immune checkpoint inhibitor-associated arterial thromboembolism would be included in this group
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
- Plain-language title
- Studying clot risk in lung cancer patients receiving immunotherapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 April 2026